A. Katharina Ceranski

A. Katharina Ceranski

Auto-generated profile, based on publicly available information

A. Katharina Ceranski

Hopp Children’s Cancer Center (KiTZ)

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 January 2025 in Cancer Communications
Verified
Journal Article
Open access
JJJia Xiang Jin
Jia Xiang Jin
FFFabia Fuchslocher
Fabia Fuchslocher
MCMartha Carreno‐Gonzalez
Martha Carreno‐Gonzalez
FZFelina Zahnow
Felina Zahnow
ACA. Katharina Ceranski
A. Katharina Ceranski
TGThomas G. P. Grünewald
Thomas G. P. Grünewald

26 April 2024 in bioRxiv
Verified
Preprint
Open access
PDF file
EVEndrit Vinca
Endrit Vinca
AEAnna C. Ehlers
Anna C. Ehlers
ARAlina Ritter
Alina Ritter
DODavid Obermeier
David Obermeier
CFCornelius M. Funk
Cornelius M. Funk
SOShunya Ohmura
Shunya Ohmura
Ewing sarcoma (EwS) is a highly aggressive bone and soft-tissue associated cancer for which there are no effective targeted therapeutics available. Genetically, EwS is driven by aberrantly active EWSR1::ETS fusion transcription factors, most commonly EWSR1::FLI1. Despite their unique expression in EwS, all attempts to effectively target these fusion oncoproteins clinically were not yet successful, wherefore alternative targets are required. Here, we functionally characterize the evolutionarily conserved oxidative stress regulator glutaredoxin 3 (GLRX3) as a EwS-specific and EWSR1::FLI1-dependent vulnerability. Through integration of transcriptome-profiling, conditional drug screens in 3D cultures, and functional experiments, we discover that GLRX3 promotes EwS growth in vitro and in vivo, and that it has a key role in mitigation of oxidative stress and maintenance of iron homeostasis. These GLRX3 functions can be exploited in both GLRX3-high and -low expressing EwS cells by targeted therapeutics including CDK4/6 inhibitors and inducers of apoptotic and ferroptotic cell death. Collectively, our results exemplify how the interplay of an evolutionarily conserved oxidative stress regulator with a dominant oncogene can promote malignancy but provide opportunities for predictive diagnostics and personalized therapy.

21 May 2025 in bioRxiv
Verified
Preprint
Open access
PDF file
MCMartha J. Carreño-Gonzalez
Martha J. Carreño-Gonzalez
KHKimberley M. Hanssen
Kimberley M. Hanssen
ASAhmed Sadik
Ahmed Sadik
AHAlessa L. Henneberg
Alessa L. Henneberg
MKMaximilian M. L. Knott
Maximilian M. L. Knott
TGThomas G. P. Grünewald
Thomas G. P. Grünewald
How activational changes of driver oncogenes can promote metabolic reprogramming and cancer progression is largely uncharted territory. To address this issue, we employed Ewing sarcoma (EwS) as a model as it is driven by a single driver oncogene, namely chimeric EWSR1::ETS fusion transcription factors, whose fluctuating expression levels promote diverse transcriptional programs. While EWSR1::ETS-high cells display a rather sessile but proliferative phenotype and EWSR1::ETS-low cells are more invasive, the mechanisms underlying these different phenotypes remain poorly characterized. Here, using an integrative functional genomics approach, we show that low EWSR1::ETS fusion activity in patient tumors associates with poor outcome and increased signaling of the aryl hydrocarbon receptor (AHR). AHR signaling enrichment correlates with increased tumor infiltration by immunosuppressive cells and worse overall patient survival. Knockdown of EWSR1::ETS in EwS spheroid models cultured in human plasma-like media strongly alters tryptophan metabolism resulting in increased secretion of the AHR ligand kynurenine. Silencing of EWSR1::ETS reduced killing of EwS cells by natural killer (NK) cells, while AHR silencing increases NK cell-mediated killing. From a cell-intrinsic perspective, AHR knockdown inhibits proliferation, clonogenic, and spheroidal growth of EwS cells in vitro, which can be recapitulated by pharmacological AHR inhibition. Furthermore, AHR knockdown decreases tumor growth and metastasis in vivo. Collectively, our results illustrate how oncogene-mediated metabolic reprogramming of amino acid metabolism can translate into more aggressive disease phenotypes in cancer.

9 July 2024 in bioRxiv
Verified
Preprint
Open access
PDF file
ACA. Katharina Ceranski
A. Katharina Ceranski
MCMartha J. Carreño-Gonzalez
Martha J. Carreño-Gonzalez
AEAnna C. Ehlers
Anna C. Ehlers
ZKZuzanna Kolodynska
Zuzanna Kolodynska
EVEndrit Vinca
Endrit Vinca
TGThomas G. P. Grünewald
Thomas G. P. Grünewald
SUMMARY: Ewing sarcoma (EwS) cell line culture largely relies on standard techniques, which do not recapitulate physiological conditions. Here, we report on a physiologically improved, feasible, and cost-efficient EwS cell culture technique employing an advanced medium composition, reduced fetal calf serum, and spheroidal growth. Functional in vitro assays and transcriptome profiling demonstrated that these refined conditions better recapitulate proliferation rates of patient tumors as well as hypoxic conditions relevant for EwS pathophysiology. Moreover, transcriptional signatures associated with the oncogenic activity of the EwS-specific FET::ETS fusion transcription factors in the refined culture conditions were shifted from proliferative towards metabolic gene signatures. The herein presented optimized physiological EwS cell culture technique provides a broadly applicable approach for enhanced in vitro modeling relevant to advancing EwS research and the validity of experimental results. MOTIVATION: Cell culture remains the main platform to model EwS for research purposes. Yet, concerns exist about the limitations of standard in vitro techniques to adequately reflect physiological conditions. In this study, we refined EwS cell culture methods to increase modeling capacity while ensuring a practical and cost-effective handling, thereby broadening their applicability within the scientific community.